Company intelligence / Profile preview
ExeGi Pharma
Rockville, Maryland, United Statesexegipharma.com ↗
- Ownership
- Private
- Employees
- ~23
- Development stage
- Commercial
01
Overview
ExeGi Pharma has commercial products including Visbiome probiotic products for various digestive conditions. Their lead investigational drug candidate EXE-346 received FDA IND clearance in January 2023 for clinical trials in patients with excessive stool frequency following ileal pouch-anal anastomosis (J-Pouch).
- Therapeutic areas
- GastroenterologyMetabolic DisordersInfectious Diseases
- Modalities
- Live biotherapeutic productsProbiotics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Carbonfund.org
Beyond the preview
Go deeper on ExeGi Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExeGi Pharma.